Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

C. Garrett Rappazzo(Adimab (United States)), Laura M. Walker(Children's Hospital of Philadelphia), Chengzi I. Kaku(Scripps Institution of Oceanography), Bronwyn M. Gunn(Washington State University), John M. Dye(United States Army Medical Research Institute of Infectious Diseases), Ralph S. Baric(University of North Carolina at Chapel Hill), Michael B. Battles(Adimab (United States)), Thomas J. Yockachonis(Washington State University), Cecilia M. O’Brien(United States Army Medical Research Institute of Infectious Diseases), Jonathan Belk(Adimab (United States)), Lisa E. Gralinski(University of North Carolina at Chapel Hill), Daniel Wrapp(Duke University), Mrunal Sakharkar(Adimab (United States)), Andrew S. Herbert(United States Army Medical Research Institute of Infectious Diseases), Yixuan J. Hou(University of North Carolina at Chapel Hill), Laura M. Deveau(Adimab (United States)), Dennis R. Burton(Scripps Research Institute), James E. Voss(Scripps Research Institute), James C. Geoghegan(Adimab (United States)), Linlin Yang(Scripps Research Institute), Linghang Peng(Scripps Research Institute), Deli Huang(Scripps Research Institute), Trevor Scobey(University of North Carolina at Chapel Hill), David Nemazee(Scripps Research Institute), Jason S. McLellan(The University of Texas at Austin), Michael E. Brown(Adimab (United States)), Longping V. Tse(Saint Louis University)
Science
January 25, 2021
Cited by 394


Related Papers